Vectibix(TM) (panitumumab) Receives Positive Opinion for Marketing Authorization in the European Union

Opinion Based on Positive Benefit / Risk Assessment in Patients with Metastatic Colorectal Cancer with Non-Mutated KRAS

Amgen (NASDAQ:AMGN) today announced that the European Committee
for Medicinal Products for Human Use (CHMP) has issued a positive
opinion recommending a conditional marketing authorization for
Vectibix(TM) (panitumumab) in the European Union (EU) for patients
with refractory metastatic colorectal cancer with non-mutated
(wild-type) KRAS genes.

"We are pleased that Vectibix has received a positive opinion for
conditional approval so patients in the EU have further treatment
options for metastatic colorectal cancer," said Willard Dere, M.D.,
senior vice president and international chief medical officer at
Amgen. "This is an important step forward in personalized cancer care.
Amgen is committed to discovering, validating and implementing novel
clinically relevant biomarkers to help physicians provide the right
treatment for patients."

The CHMP positive opinion for Vectibix is based on a positive
benefit / risk assessment in a patient population that currently has
few treatment options available to them. As part of the CHMP review,
clinical data supporting the utility of KRAS mutation status as a
biomarker for clinical outcome were provided. These data were
evaluated in combination with the overall clinical benefit observed in
the pivotal "408" study and safety database available. The KRAS data
will be presented for the first time at the 14th European Cancer
Conference, Barcelona, on September 25th in the Presidential
Symposium.

KRAS plays an important role in cell growth regulation and
oncogenesis. Anti-epidermal growth factor receptor (EGFR) therapies
work by blocking the activation of EGFR, thereby inhibiting downstream
events that lead to malignant signaling. However, in patients with
tumors harboring a mutated or activated KRAS, the KRAS protein is
always turned "on" regardless of whether EGFR has been activated or
therapeutically inhibited. Thus, in patients with mutated KRAS,
signaling continues despite anti-EGFR therapy. Mutant KRAS is detected
in approximately 40 percent of mCRC.

About Vectibix

Vectibix (panitumumab) the first fully human IgG2 monoclonal
antibody (MAb), targets the epidermal growth factor receptor (EGFr), a
protein that plays an important role in cancer cell signalling. With
its demonstrated efficacy, low rate of infusion reactions and
immunogenicity, and convenient Q2W dosing schedule Vectibix provides
an important option in the management of metastatic CRC patients.
Ongoing Phase 3 trials are exploring the potential of administering
Vectibix in combination with chemotherapy for first- and second-line
mCRC.

Approved by the FDA in September 2006 Vectibix is indicated for
the treatment of patients with epidermal growth factor receptor (EGFr)
expressing metastatic colorectal cancer after disease progression on,
or following fluoropyrimidine, oxaliplatin and irinotecan containing
chemotherapy regimens. The effectiveness of Vectibix for the treatment
of metastatic colorectal carcinoma is based on progression-free
survival. Currently no data are available that demonstrate an
improvement in disease related symptoms or increased survival with
Vectibix.

In the EU, Vectibix is indicated as monotherapy for the treatment
of patients with metastatic colorectal carcinoma expressing EGFR with
non-mutated KRAS tumours and after failure of fluoropyrimidine-,
oxaliplatin-, and irinotecan-containing chemotherapy regimens.

Important Product Safety Information - U.S.

Dermatologic toxicities, related to Vectibix blockade of EGF
binding and subsequent inhibition of EGF receptor-mediated signalling
pathways, included but were not limited to dermatitis acneiform,
pruritus, erythema, rash, skin exfoliation, paronychia, dry skin and
skin fissures. Dermatologic toxicities were reported in 89 percent of
patients treated with Vectibix and were severe in 12 percent of
patients. Severe dermatologic toxicities were complicated by
infection, including sepsis, septic death and abscesses requiring
incisions and drainage. Vectibix may need to be withheld or
discontinued for severe dermatologic toxicities.

Severe infusion reactions occurred with Vectibix in approximately
one percent of patients. Severe infusion reactions were identified as
anaphylactic reactions, bronchospasm, fever, chills and hypotension.
Although fatal infusion reactions have not been reported with
Vectibix, they have occurred with other monoclonal antibody products.
Severe infusion reactions require stopping the infusion and possibly
permanently discontinuing Vectibix, depending on the severity and / or
persistence of the reaction.

About Amgen

Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realise the new science's promise by bringing safe,
effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics has changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.

Forward Looking Statement

This news release contains forward-looking statements that are
based on management's current expectations and beliefs and are subject
to a number of risks, uncertainties and assumptions that could cause
actual results to differ materially from those described. All
statements, other than statements of historical fact, are statements
that could be deemed forward-looking statements, including estimates
of revenues, operating margins, capital expenditures, cash, other
financial metrics, expected legal, arbitration, political, regulatory
or clinical results or practices, customer and prescriber patterns or
practices, reimbursement activities and outcomes and other such
estimates and results. Forward-looking statements involve significant
risks and uncertainties, including those discussed below and more
fully described in the Securities and Exchange Commission (SEC)
reports filed by Amgen, including Amgen's most recent annual report on
Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K.
Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for
additional information on the uncertainties and risk factors related
to our business. Unless otherwise noted, Amgen is providing this
information as of Sept. 25, 2007, and expressly disclaims any duty to
update information contained in this news release.

No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and become a
commercial product. Further, preclinical results do not guarantee safe
and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modeled by computer or cell culture systems or animal
models. The length of time that it takes for us to complete clinical
trials and obtain regulatory approval for product marketing has in the
past varied and we expect similar variability in the future. We
develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates
that are derived from relationships may be subject to disputes between
the parties or may prove to be not as effective or as safe as we may
have believed at the time of entering into such relationship. Also, we
or others could identify safety, side effects or manufacturing
problems with our products after they are on the market. Our business
may be impacted by government investigations, litigation and products
liability claims. We depend on third parties for a significant portion
of our manufacturing capacity for the supply of certain of our current
and future products and limits on supply may constrain sales of
certain of our current products and product candidate development.

In addition, sales of our products are affected by the
reimbursement policies imposed by third-party payors, including
governments, private insurance plans and managed care providers and
may be affected by regulatory, clinical and guideline developments and
domestic and international trends toward managed care and health care
cost containment as well as U.S. legislation affecting pharmaceutical
pricing and reimbursement. Government and others' regulations and
reimbursement policies may affect the development, usage and pricing
of our products. In addition, we compete with other companies with
respect to some of our marketed products as well as for the discovery
and development of new products. We believe that some of our newer
products, product candidates or new indications for existing products,
may face competition when and as they are approved and marketed. Our
products may compete against products that have lower prices,
established reimbursement, superior performance, are easier to
administer, or that are otherwise competitive with our products. In
addition, while we routinely obtain patents for our products and
technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors and there can be no guarantee of our ability to obtain or
maintain patent protection for our products or product candidates. We
cannot guarantee that we will be able to produce commercially
successful products or maintain the commercial success of our existing
products. Our stock price may be affected by actual or perceived
market opportunity, competitive position, and success or failure of
our products or product candidates. Further, the discovery of
significant problems with a product similar to one of our products
that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our business
and results of operations.

The scientific information discussed in this news release related
to our product candidates is preliminary and investigative. Such
product candidates are not approved by the U.S. Food and Drug
Administration (FDA) or European Medicines Agency (EMEA), and no
conclusions can or should be drawn regarding the safety or
effectiveness of the product candidates. Only the FDA, EMEA or
comparable regulatory body can determine whether the product
candidates are safe and effective for the use(s) being investigated.
Further, the scientific information discussed in this news release
relating to new indications for our products is preliminary and
investigative and is not part of the labeling approved by the FDA or
EMEA for the products. The products are not approved for
the investigational use(s) discussed in this news release, and no
conclusions can or should be drawn regarding the safety or
effectiveness of the products for these uses. Only the FDA, EMEA or
comparable regulatory body can determine whether the products are safe
and effective for these uses. Healthcare professionals should refer to
and rely upon the applicable FDA- or EMEA-approved labeling for the
products, and not the information discussed in this news release.